CEMIP and breast cancer: TIMER2.0 was employed to investigate the mRNA expression level of CEMIP across a variety of cancers based on the TCGA dataset, which was expressed higher in 13 kinds of cancers other than normal controls (p < 0.05), including BC, but lower in other three types of cancer (Figure 1A).